Journal article · 2019 · Open access
A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy
Journal of Intensive and Critical Care, 5(2) · Published 1 January 2019
In brief
“A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy” is a 2019 journal article by Christopher Anthony Duplessis and 14 co-authors, published in Journal of Intensive and Critical Care. OpenAlex counts 27 citations as of 15 November 2026, which puts it in the top 7% of works published in 2019 by citations. It is open access: the full text is free to read at Journal of Intensive and Critical Care.
- Citations
- 27
- Most cited in
- 2021 (7)
- Field-weighted impact
- 1.71
- Authors
- 15
Abstract
The advent and increasing prevalence of antimicrobial resistance commensurate with the absence of novel antibiotics on the horizon raises the spectre of untreatable infections. We must now grapple with infections stemming from extensively multi- and pan-drug resistant bacterial strains. Potential non-antibiotic options to treat Multi-Drug Resistant (MDR) infections include bacteriophages and there has been much fervour in resurrecting research into its clinical use. Although not subjected to the contemporary rigorous scientific standards for clinical trials, there appears to be an abundance of data purporting safety of bacteriophage therapy regardless of administration route. The US Navy and Adaptive Phage Therapeutics have taken a precision approach to development of bacteriophage therapy. Herein, as opposed to fixed phage cocktails, we exploit the quintessential example of personalized medicine by acquiring the patient’s infecting isolate and identifying a phage cocktail proven to lyse the bacteria. As we prepare to execute our FDA regulated clinical phase II bacteriophage therapeutic trials in the ensuing year(s), we have engaged in numerous compassionate use eIND cases to provide potentially life-saving bacteriophage treatment to patients either failing conventional antibiotic therapy due to MDR resistance, or stemming from an inability to secure definitive source control. In all eIND cases, “personalized” bacteriophage cocktails were selected which “targeted” the infecting organism. This case series reports upon 13 emergencies investigational new drug (eIND) cases whereby patients failing antibiotic therapy safely received bacteriophage mixtures (cocktails) without identifying any bacteriophagemediated adverse effects. Adjudicated microbiologic eradication of the targeted bacterial isolate was achieved in 11 cases, while 6 cases were clinically adjudicated to have achieved therapeutic efficacy defined as clinical resolution. The balance of non-resolved cases was secondary to curtailed therapy (patient expiring), noninfectious mediated organ failure, or relapse of infection from biofilm-mediated infections.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Duplessis, C. A., Stockelman, M. G., Hamilton, T., Merril, G., Brownstein, M., Bishop‐Lilly, K. A., Schooley, R. T., Henry, M., Horne, B., Sisson, B. M., Quiñónes, J., Aslam, S., Lavergne, S. N., Nir‐Paz, R., & Biswas, B. (2019). A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy. Journal of Intensive and Critical Care, 5(2). https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf
MLA 9
Duplessis, Christopher Anthony, et al. “A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy.” Journal of Intensive and Critical Care, vol. 5, no. 2, 2019. https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf.
Chicago
Duplessis, Christopher Anthony, Michael G. Stockelman, Theron Hamilton, Greg Merril, Michael Brownstein, Kimberly A. Bishop‐Lilly, Robert Turner Schooley, et al. 2019. “A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy.” Journal of Intensive and Critical Care 5 (2). https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf.
Harvard
Duplessis, C. A. et al. (2019) ‘A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy’, Journal of Intensive and Critical Care, 5(2). Available at: https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf.
IEEE
C. A. Duplessis et al., “A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy,” Journal of Intensive and Critical Care, vol. 5, no. 2, 2019.
BibTeX
@article{duplessis2019case,
title = {{A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy}},
author = {Duplessis, Christopher Anthony and Stockelman, Michael G. and Hamilton, Theron and Merril, Greg and Brownstein, Michael and Bishop‐Lilly, Kimberly A. and Schooley, Robert Turner and Henry, Matthew and Horne, Bri’Anna and Sisson, Brittany M. and Quiñónes, Javier and Aslam, Saima and Lavergne, Sidonie N. and Nir‐Paz, Ran and Biswas, Biswajit},
journal = {Journal of Intensive and Critical Care},
year = {2019},
volume = {5},
number = {2},
url = {https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2020 | 2 | |
| 2021 | 7 | |
| 2022 | 7 | |
| 2023 | 6 | |
| 2024 | 3 | |
| 2025 | 2 |
Its field-weighted citation impact is 1.71: it has been cited 1.71 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
- phage therapy
- multidrug-resistant bacteria
- compassionate use
- phage safety
- antimicrobial resistance
- biofilm-associated infections
- microbiologic eradication
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Duplessis, C. A., Stockelman, M. G., Hamilton, T., Merril, G., Brownstein, M., Bishop‐Lilly, K. A., Schooley, R. T., Henry, M., Horne, B., Sisson, B. M., Quiñónes, J., Aslam, S., Lavergne, S. N., Nir‐Paz, R., & Biswas, B. (2019). A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy. Journal of Intensive and Critical Care, 5(2). https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf
How many times has this paper been cited?
27 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Journal of Intensive and Critical Care.
Who wrote this paper?
Christopher Anthony Duplessis, Michael G. Stockelman, Theron Hamilton, Greg Merril, Michael Brownstein, Kimberly A. Bishop‐Lilly, Robert Turner Schooley, Matthew Henry, Bri’Anna Horne, Brittany M. Sisson, Javier Quiñónes, Saima Aslam and 3 more.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.